In this regard, in patients with severe rheumatoid arthritis undergoing periodical treatment with anti-TNF-α-therapy and ongoing disease activity, low adiponectin levels clustered with metabolic syndrome features that reportedly contribute to atherogenesis in rheumatoid arthritis [13]. This evidence concerns the gene ADIPOQ and metabolic syndrome.